184 related articles for article (PubMed ID: 32368217)
1. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy.
Weinfeld D; Westin U; Hellkvist L; Mellqvist UH; Jacobsson I; Cardell LO
Allergy Asthma Clin Immunol; 2020; 16():31. PubMed ID: 32368217
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
[TBL] [Abstract][Full Text] [Related]
3. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.
Ahlbeck L; Ahlberg E; Stuivers L; Björkander J; Nyström U; Retsas P; Govindaraj D; Jenmalm MC; Duchén K
Clin Exp Allergy; 2023 Aug; 53(8):809-820. PubMed ID: 37013723
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up.
Adlany YK; Šošić L; Senti G; Lang CCV; Wüthrich B; Kündig TM; Johansen P
J Allergy Clin Immunol Glob; 2023 Feb; 2(1):43-50. PubMed ID: 37780115
[TBL] [Abstract][Full Text] [Related]
5. A 5-Year Open-Label Follow-up of a Randomized Double-Blind Placebo-Controlled Trial of Intralymphatic Immunotherapy for Birch and Grass Allergy Reveals Long-term Beneficial Effects.
Hjalmarsson E; Hellkvist L; Karlsson A; Winquist O; Kumlien Georén S; Westin U; Cardell LO
J Investig Allergol Clin Immunol; 2023 Oct; 33(5):362-372. PubMed ID: 37843385
[TBL] [Abstract][Full Text] [Related]
6. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial.
Hylander T; Larsson O; Petersson-Westin U; Eriksson M; Kumlien Georén S; Winqvist O; Cardell LO
Respir Res; 2016 Jan; 17():10. PubMed ID: 26817454
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
8. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
Hylander T; Latif L; Petersson-Westin U; Cardell LO
J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
[TBL] [Abstract][Full Text] [Related]
9. High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase.
Hellkvist L; Hjalmarsson E; Weinfeld D; Dahl Å; Karlsson A; Westman M; Lundkvist K; Winqvist O; Georén SK; Westin U; Cardell LO
Allergy; 2022 Mar; 77(3):883-896. PubMed ID: 34379802
[TBL] [Abstract][Full Text] [Related]
10. Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen.
Ahlbeck L; Ahlberg E; Björkander J; Aldén C; Papapavlou G; Palmberg L; Nyström U; Retsas P; Nordenfelt P; Togö T; Johansen P; Rolander B; Duchén K; Jenmalm MC
Clin Exp Allergy; 2022 Jun; 52(6):747-759. PubMed ID: 35332591
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Safety, Efficacy, and Compliance of Intralymphatic Immunotherapy for Allergic Rhinoconjunctivitis: A Systematic Review and Meta-Analysis.
Wang W; Wang X; Wang H; Wang X
Int Arch Allergy Immunol; 2023; 184(8):754-766. PubMed ID: 37105134
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study.
Schmid JM; Nezam H; Madsen HH; Schmitz A; Hoffmann HJ
Clin Transl Allergy; 2016; 6():19. PubMed ID: 27231527
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
14. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
15. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
16. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
19. Intralymphatic Immunotherapy (ILIT) With Bee Venom Allergens: A Clinical Proof-of-Concept Study and the Very First ILIT in Humans.
Chabot A; Senti G; Erdmann I; Prinz BM; Wüthrich B; Šošić L; Kündig TM; Johansen P
Front Allergy; 2022; 3():832010. PubMed ID: 35386649
[TBL] [Abstract][Full Text] [Related]
20. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy.
Aasbjerg K; Backer V; Lund G; Holm J; Nielsen NC; Holse M; Wagtmann VR; Würtzen PA
Clin Exp Allergy; 2014 Mar; 44(3):417-28. PubMed ID: 24734285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
